Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis

Journal of Rheumatology

Volumn 37, Issue 10, 2010, Pages 2064-2070

  Cavagna, Lorenzo ^a   Caporali, Roberto ^a   Klersy, Catherine ^a   Ghio, Stefano ^a   Albertini, Riccardo ^a   Scelsi, Laura ^a   Moratti, Remigio ^a   Bonino, Claudia ^a   Montecucco, Carlomaurizio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Brain natriuretic peptide; NT pro brain natriuretic peptide; Pulmonary arterial hypertension; Systemic sclerosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; CARBON MONOXIDE; CREATININE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; DYSPNEA; FEMALE; HEART CATHETERIZATION; HEART INDEX; HEART OUTPUT; HEART RIGHT ATRIUM PRESSURE; HUMAN; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS;

ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL MARKERS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY;

EID: 77957863809     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090997     Document Type: Article

References (39)

1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4.
2. Mukerjee D, St. George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated with pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
3. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800.
4. Distler O, Pignone A. Pulmonary arterial hypertension and rheumatic diseases: from diagnosis to treatment. Rheumatology 2006;45 Suppl 4:22-5.
5. Cox SR, Walker JG, Coleman M, Rischmueller M, Proudman S, Smith MD, et al. Isolated pulmonary hypertension in scleroderma. Intern Med J 2005;35:28-33.
6. Trad S, Amoura Z, Beigelman C, Haroche J, Costedoat N, Du Boutin LTH, et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006;54:184-91.
7. Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007;37:485-94.
8. Trow TK, McArdle JR. Diagnosis of pulmonary arterial hypertension. Clin Chest Med 2007;28:59-73.
9. Rich S, editor. Executive summary from the World Symposium on Primary Pulmonary Hypertension, Evian, France, 1998. Geneva: World Health Organization.
10. Souza R, Bogossian HB, Humbert M, Jardim C, Rabelo R, Amato MB, et al. N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension. Eur Respir J 2005;25:509-13.
11. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006;129:1313-21.
12. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-70.
13. Leuchte HH, Holzapfel M, Baumgartner RA, Neurohr C, Vogeser M, Behr J. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest 2005;128:2368-74.
14. Mukerjee D, Yap LB, Holmes AM, Nair D, Ayrton P, Black CM, et al. Significance of plasma N-terminal probrain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003;97:1230-6.
15. Hesselstrand R, Ekam R, Eskilson J, Isaksson A, Scheja A, Ohlin AK, et al. Screening for pulmonary arterial hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology 2005;44:366-71.
16. Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, et al. Role of N-terminal brain natriuretic peptide (NT-proBNP) in scleroderma associated with pulmonary arterial hypertension. Eur Heart J 2006;27:1485-94.
17. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008;58:284-91.
18. Kallistratos MS, Dritsas A, Laoutaris ID, Cokkinos DV. Incremental value of N-terminal pro-brain natriuretic peptide over left ventricle ejection fraction and aerobic capacity for estimating prognosis in heart failure patients. J Heart Lung Transplant 2008;27:1251-6.
19. Sakurai S, Adachi H, Hasegawa A, Hoshizaki H, Oshima S, Taniguchi K, et al. Brain natriuretic peptide facilitates severity classification of stable chronic heart failure with left ventricular dysfunction. Heart 2003;89:661-2.
20. Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J 2008;38:101-13.
21. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
22. Grenier P, Valeyre D, Cluzel P, Brauner MW, Lenoir S, Chastang C. Chronic diffuse interstitial lung disease: diagnostic value of chest radiography and high-resolution CT. Radiology 1991;179:123-32.
23. Zompatori M, Bnà C, Poletti V, Spaggiari E, Ormitti F, Calabro E, et al. Diagnostic imaging of diffuse infiltrative disease of the lung. Respiration 2004;71:4-19. (Pubitemid 38223759)
24. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997;169:977-83.
25. Steen V, Graham G, Conte C, Owens G, Medsger TA Jr. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992;35:765-70.
26. Cutolo M, Pizzorni C, Sulli A. Capillaroscopy. Best Pract Res Clin Rheumatol 2005;19:437-52.
27. Valentini G, D'Angelo S, Della Rossa A, Bencivelli W, Bombardieri S. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003;62:904-5.
28. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-63.
29. Rehman SU, Jannuzzi JL Jr. Natriuretic peptide testing in clinical medicine. Cardiol Rev 2008;16:240-9.
30. Johannes M, Falkensammer G, Hiemetzberger R, Hanno U, Griesmacher A, Pachinger O. Head to head comparison of B-type natriuretic peptide (BNP) and NT-proBNP in daily clinical practice. Int J Cardiol 2008;124:244-6.
31. Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89:745-51.
32. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82.
33. Ghio S, Di Matteo A, Scelsi L, Klersy C, Orsolini P, Monti L, et al. Plasma brain natriuretic peptide is a marker of right ventricular overload in pulmonary hypertension associated to HIV infection. Eur Heart J Suppl 2004;6:35-9.
34. Steen V. Advancements in diagnosis of pulmonary arterial hypertension in scleroderma. Arthritis Rheum 2005;52:3698-700.
35. Charloux A, Chaouat A, Piquard F, Brandenberger G, Weitzenblum E, Geny B. Renal hyporesponsiveness to brain natriuretic peptide: both generation and renal activity of cGMP are decreased in patients with pulmonary hypertension. Peptides 2006;27:2993-9.
36. Shah SJ, Thenappan T, Rich S, Tian S, Archer SL, Gomberg-Maitland M, et al. Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation 2008;117:2475-83.
37. Ciurzynski M, Bienias P, Lichodziejewska B, Kurnicka K, Szewczyk A, Glinske-Wielochowska M, et al. Non invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis. Clin Rheumatol 2008;27:991-7.
38. Plastiras SC, Karadimitrakis SP, Kampolis C, Moutsopoulos HM, Tzelepis GE. Determinants of pulmonary arterial hypertension in scleroderma. Semin Arthritis Rheum 2007;36:392-6.
39. Allanore Y, Borderie D, Meune C, Cabanes L, Weber S, Ekindjian OG, et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum 2003;48:3503-8.